Name
Ibrutinib
Alternate Names
Imbruvica
PCI-32765
RESONATE
Abbreviations
None
Category
Chemotherapy
Subcategory
Bruton tyrpsine kinase (Btk)
NSC Number
748645
Primary Site
Histology
None
Remarks
The FDA has given ibrutinib the breakthrough therapy designation. The FDA has granted approval for this drug November 13, 2013. This drug is in additional clinical trials looking at its effect in combination with other agents in treatment of other types of leukemic and lymphoid malignancies.
March 4, 2016 The FDA has approved Imbruvica (ibrutinib) as first course treatment for patients with chronic lymphocytic leukemia.
August 4, 2017: FDA has approved ibrutinib (Imbruvica) for adult patients with chronic graft versus host disease after failure of one or more lines of systemic therapy, making it the first FDA-approved therapy for the treatment of cGVHD.
April 21, 2020 The FDA expanded the indication of ibrutinib (IMBRUVICA) to include its combination with rituximab for the initial treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
March 4, 2016 The FDA has approved Imbruvica (ibrutinib) as first course treatment for patients with chronic lymphocytic leukemia.
August 4, 2017: FDA has approved ibrutinib (Imbruvica) for adult patients with chronic graft versus host disease after failure of one or more lines of systemic therapy, making it the first FDA-approved therapy for the treatment of cGVHD.
April 21, 2020 The FDA expanded the indication of ibrutinib (IMBRUVICA) to include its combination with rituximab for the initial treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Coding
This drug should be coded